ALUMIS INC. — Form SCHEDULE 13D
Filed August 17, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 8/100
What the filing says
This is Exhibit A to a Schedule 13D filing dated August 17, 2026, showing an agreement among Foresite Capital entities (Funds V and VI, and Opportunity Fund V) and James B. Tananbaum to file a joint Schedule 13D regarding Common Stock of Latigo Biotherapeutics, Inc. The exhibit does not disclose the target company name, share count, percentage ownership, dollar amount of investment, or transaction details—only the agreement to file jointly and the signatory entities.
Why this rating
Filing exhibits are administrative/procedural; substance cannot be assessed without the main Schedule 13D, which should disclose ownership %, shares, and intent. Routine disclosure boilerplate.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.